Biosimilar Antibodies

The Anti-TNFRSF7/CD27 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TNFRSF7/CD27, a critical receptor involved in the regulation of T and B cell function. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, exhibiting a molecular weight of approximately 145 kDa. For isotype control purposes, Human IgG2 kappa, Isotype Control is recommended. This product is essential for research focusing on immune response modulation and the study of diseases characterized by altered TNFRSF7/CD27 activity.

Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-3 receptor alpha, also known as CD123. This antibody has a molecular weight of approximately 146.14 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This antibody is designed for precise targeting, making it suitable for a range of research applications focusing on the biology and pathophysiology of IL-3Ra/CD123.

LGN-523 (AML-01) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD98. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, featuring a predicted molecular weight of 145.66 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. LGN-523 (AML-01) is suitable for a variety of research applications focusing on the role of CD98 in cellular processes.

DFRF4539A (RG-7598) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets FcRH5/IRTA2/CD307e, a protein expressed on the surface of certain immune cells. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a molecular weight of approximately 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

CTX-2026 is a fully human monoclonal antibody that specifically targets CD277, a protein implicated in the immunological landscape of tumors. This antibody has demonstrated a potent anti-tumor effect in ovarian cancer models, suggesting its utility in oncological research focused on the modulation of tumor microenvironments. CTX-2026 is ideal for investigations into cancer biology, particularly for studies aiming to elucidate the role of CD277 in tumor immunology and therapeutic intervention.

The Anti-Fy3 Antibody (MIMA-29) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target the human Fy3 antigen. For optimal experimental control, it is recommended to use Mouse IgG2a kappa Isotype Control alongside this antibody to accurately assess antibody specificity and ensure accurate data interpretation.

Imsidolimab (ANB 019) is a high-affinity humanized monoclonal antibody that targets IL-36 receptor (IL-36R), effectively antagonizing IL-36 cytokine signal transduction. This antibody is designed for potential therapeutic use in managing generalized pustular psoriasis (GPP) and various other inflammatory skin conditions. Its specificity for IL-36R makes it a valuable tool for research and treatment development in dermatological inflammation.

Peluntamig is a bispecific antibody of the H-γ1_L-κ type that targets both CD47 and DLL3. This dual specificity allows for enhanced therapeutic potential in oncology research, leveraging the roles of CD47 in "don't eat me" signal inhibition and DLL3 in cancer stem cell signaling pathways.

Tiragolumab functions as an immune checkpoint inhibitor by targeting the T-cell immunoglobulin and ITIM domain (TIGIT). This monoclonal antibody can be utilized either as a monotherapy or in conjunction with Atezolizumab, a PD-L1 inhibitor, to potentially enhance therapeutic efficacy against a variety of solid tumors, with a notable application in the treatment of non-small cell lung cancer (NSCLC). This dual approach may offer a strategic advantage in the modulation of immune responses in oncology settings.

Brentuximab is a monoclonal antibody that specifically targets CD30, a cell surface antigen. This antibody is conjugated with monomethyl auristatin E (MMAE), resulting in the antibody-drug conjugate known as Brentuximab vedotin. This conjugate has been shown to induce apoptosis in primary effusion lymphoma cells and demonstrates potent antitumor activity. In vitro studies reveal that Brentuximab vedotin has an IC50 of 10 nM against human CD30-positive cancer cells, highlighting its efficacy in targeting and eliminating malignant cells expressing CD30.

The Anti-PACAP38 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the peptide PACAP38. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, the Human IgG4 kappa Isotype Control is recommended. This antibody is designed for the precise identification and study of PACAP38's role and function in biological systems.

Venanprubart is a human IgG4 κ monoclonal antibody targeting BTLA (B and T Lymphocyte Attenuator). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and study of BTLA's role in immune regulation, making it an essential tool for immunology research.

NI-0701 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG2 kappa, Isotype Control. NI-0701 is applicable in research focused on the biological roles and therapeutic targeting of the chemokine CCL5/RANTES.

Podentamig is a chimeric antibody designed to target CD3E and TNFRSF17. It features a unique VH-VH'-(scFv-heavy -λ) configuration, enhancing its specificity and binding affinity for these antigens. This antibody is engineered for advanced research applications, focusing on the modulation of immune responses and the study of B-cell malignancies.

Timcevibart is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Ibalizumab (TMB-355) is a humanized IgG4 monoclonal antibody designed to inhibit HIV-1 entry into cells by specifically binding to the CD4 receptor. This targeted mechanism makes Ibalizumab a valuable tool for research into the prevention and treatment of HIV-1 infection.

Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody specifically designed to target interleukin-21. This therapeutic protein is engineered to bind selectively to interleukin-21, a cytokine implicated in the pathogenesis of various autoimmune diseases, thereby modulating immune responses and providing potential therapeutic benefits in disorders characterized by excessive or aberrant cytokine activity.

Oloctinebart is a humanized IgG4-kappa monoclonal antibody targeting LGALS3. This antibody is specifically designed to inhibit the formation of amyloid beta oligomers, which are implicated in the pathogenesis of Alzheimer's disease and other amyloid-related disorders. Oloctinebart's targeted action makes it a valuable tool for research focused on the molecular mechanisms of amyloidosis and potential therapeutic interventions.

Gatralimab (GZ-402668) is an IgG1 monoclonal antibody specifically designed to target CD52. This antibody is utilized in various research studies to investigate its potential therapeutic applications and mechanism of action in modulating immune responses.

ALT-100 is a humanized IgG1 monoclonal antibody specifically designed to target NAMPT (Nicotinamide phosphoribosyltransferase). This antibody is engineered from the human IgG1 subclass and is suitable for various immunological applications where NAMPT is implicated, including cancer research and inflammatory diseases. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Devextinetug (IXT-M200) is a chimeric monoclonal antibody of the IgG2κ subtype, derived from mouse sources, specifically targeting methamphetamine molecules. This antibody is engineered for high specificity and affinity in binding methamphetamine, making it an ideal tool for research studies focused on the detection and neutralization of this compound in various biological systems.

Sofituzumab (MMUC 1206A) is a recombinant, humanized V-kappa antibody targeting MUC16. This monoclonal antibody is designed for high specificity and affinity in binding to the MUC16 antigen, making it a valuable tool for research into cancer diagnostics and therapeutics where MUC16 is a relevant biomarker.

Izenivetmab (ZTS-00075623) is a caninized monoclonal antibody of the IgG2κ isotype, specifically targeting nerve growth factor beta (NGFB). This therapeutic antibody is designed for use in canine models, facilitating the study of NGFB's role in various biological processes and potential therapeutic interventions.

Sudubrilimab (HS636) is an IgG1-kappa monoclonal antibody targeting PD-L1. This antibody is uniquely engineered with a fusion to the C-terminus of the heavy chain incorporating a TGF-β1 receptor II ectodomain (TGFBR2-ECD). This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 interaction and modulate TGF-β activity, effectively countering the immunosuppressive effects within the tumor microenvironment. This dual functionality makes it a valuable tool for research into cancer immunotherapy mechanisms and potential therapeutic interventions.

ATH3G10 is a fully human monoclonal antibody specifically designed to bind to oxidized phospholipids (OxPL). This antibody is engineered for high specificity and affinity, making it an ideal tool for research focused on oxidative stress, lipid oxidation, and related pathophysiological conditions. ATH3G10 is suitable for a variety of applications, including ELISA, Western blotting, and immunohistochemistry, facilitating detailed studies in cardiovascular diseases, inflammation, and other OxPL-associated disorders.

Evalstotug is a human IgG1 κ monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). For accurate experimental control, it is recommended to use Human IgG1 kappa isotype control.

Tecotabart is a humanized IgG1κ monoclonal antibody that specifically targets Claudin 18 (CLDN18). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

VRC-01 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the gp120 envelope glycoprotein of HIV-1. This antibody inhibits viral entry into host cells by emulating the binding mechanism of the CD4 receptor with the HIV-1 gp120 envelope glycoprotein, thereby blocking the virus's ability to infect cells. For experimental control purposes, Human IgG1 kappa, Isotype Control, is recommended. VRC-01 serves as a critical tool in the study of HIV pathogenesis and the development of therapeutic strategies against HIV infection.

The Anti-CD4 Antibody (TRX1) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CD4 receptor, a critical molecule involved in the immune response. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Livmoniplimab (ABBV-151) is a monoclonal antibody targeting the GARP/TGF-β1 complex, effectively inhibiting the release of active transforming growth factor-beta 1 (TGF-β1). Demonstrating significant anti-tumor activity in murine models of colon cancer, Livmoniplimab is primarily utilized in research focused on locally advanced or metastatic solid tumors. This antibody serves as a crucial tool in the investigation of TGF-β1's role in tumor microenvironments and cancer progression, offering potential insights into therapeutic strategies for solid tumors.

The Anti-TNFRSF21/DR6/CD358 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TNFRSF21/DR6/CD358 antigen, a member of the tumor necrosis factor receptor superfamily involved in various cellular processes including apoptosis and inflammation. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Adecatumumab (MT201) is a fully human monoclonal antibody of the IgG1 isotype designed to specifically target human EpCAM (Epithelial Cell Adhesion Molecule). This antibody is recognized for its broad expression across various adenocarcinomas. Importantly, the efficacy of Adecatumumab is independent of the K-Ras mutation status, making it a versatile tool in the research of carcinomas where EpCAM is a critical factor.

Certolizumab pegol is a recombinant, polyethylene glycolylated antigen-binding fragment derived from a humanized monoclonal antibody. It selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α), making it highly relevant for studies in rheumatoid arthritis and Crohn's disease. This specificity for TNF-α provides a critical tool for researchers investigating the pathophysiology and therapeutic interventions of these inflammatory disorders.

Epratuzumab, designated as hLL 2, is a humanized IgG1 monoclonal antibody targeting CD22, a cell surface antigen expressed predominantly on B cells. This antibody functions not only as an immunomodulatory agent but also as a tumor-imaging agent due to its specific binding to CD22. Epratuzumab has demonstrated the ability to induce phosphorylation of CD22, which plays a critical role in the modulation of B cell signaling and function. The primary applications of Epratuzumab have been in the study of non-Hodgkin’s lymphomas (NHL) and various autoimmune diseases, where it has shown potential in modulating immune responses and providing diagnostic imaging insights.

Bempikibart (ADX-914) is a humanized monoclonal antibody targeting the interleukin-7 receptor alpha (IL-7Rα). Designed for research purposes, it is utilized primarily in the study of inflammatory processes. This antibody may serve as a valuable tool in investigating the role of IL-7Rα in immune response modulation and inflammation.

Anumigilimab (CSL-324) is a human IgG4 monoclonal antibody targeting the granulocyte colony-stimulating factor (G-CSF) receptor. This antibody is designed to modulate immune responses by increasing the recruitment of neutrophils to sites of inflammation. Anumigilimab is primarily utilized in research focused on the mechanisms of neutrophil mobilization and the inflammatory response, offering potential insights into therapeutic strategies for diseases characterized by acute or chronic inflammation.

Ongericimab (JS002) is a humanized monoclonal antibody targeting PCSK9, designed to effectively lower lipid levels. This antibody is specifically developed for research applications focusing on hypercholesterolemia and hyperlipidemia, providing a valuable tool for investigating the regulation of cholesterol metabolism and assessing potential therapeutic strategies for lipid disorders.

The Anti-B7-H3/CD276 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells specifically targeting the B7-H3/CD276 antigen. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended as a suitable reference standard. This antibody is essential for studies focusing on the role of the B7-H3/CD276 pathway in immune regulation and cancer immunotherapy.

Crizanlizumab is a monoclonal antibody that targets P-selectin, effectively inhibiting its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). By blocking this interaction, Crizanlizumab plays a crucial role in preventing vaso-occlusive crises (VOCs), making it a valuable tool for the study and research of sickle cell disease pathophysiology and therapeutic interventions.

CLN-619 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target MICA (MHC class I polypeptide-related sequence A). This antibody is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with an approximate molecular weight of 146.06 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. This specificity and structure make CLN-619 ideal for detailed studies on MICA's role in immune response and its implications in various pathological conditions.

Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.

Arumakimig is a bispecific humanized antibody designed to target and neutralize both interleukin-18 (IL-18) and interleukin-1β (IL-1β). This dual specificity makes it an invaluable tool for research focused on inflammation and immune response modulation. Arumakimig is particularly suited for studies investigating the pathophysiology of diseases characterized by excessive or dysregulated inflammation, offering insights into potential therapeutic interventions.

Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-γ receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy.

Pamvatamig is a human IgG4 κ monoclonal antibody that targets both EGFR and MET receptors. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the study of signal transduction pathways and may be useful in research focused on cancer biology where EGFR and MET play critical roles.

Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) designed to simultaneously target human CD33 and human CD3 antigens. This unique configuration facilitates the recruitment and activation of T cells against CD33-expressing cells, making it a valuable tool in the study of acute myeloid leukemia (AML). Vixtimotamab's dual targeting mechanism offers a promising approach for elucidating the interactions between immune cells and leukemia cells, providing significant insights into therapeutic strategies for AML.

Nimotuzumab is a humanized IgG1 monoclonal antibody engineered to target the epidermal growth factor receptor (EGFR) with a dissociation constant (K_D) of 0.21 nM. This antibody specifically binds to the extracellular domain of EGFR, effectively inhibiting the receptor's interaction with its natural ligands. Nimotuzumab exhibits potent antitumor activity, primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism facilitates the targeted destruction of tumor cells, underscoring its utility in oncological research and therapeutic applications.

Rivabazumab is a recombinant monoclonal antibody specifically targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is designed for the precise detection and neutralization of the PcrV component, which plays a critical role in the pathogenicity of Pseudomonas aeruginosa by facilitating the injection of toxic effector proteins into host cells. Rivabazumab is utilized extensively in research focused on bacterial infection mechanisms, vaccine development, and therapeutic interventions against Pseudomonas aeruginosa.

Laprituximab (J2898A) is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This antibody serves as a precursor for the synthesis of the antibody-drug conjugate (ADC) IMGN289, utilized in targeted cancer therapy research.

Enfortumab is a humanized antibody targeting Nectin-4, suitable for conjugation with the potent microtubule disruptor, monomethyl auristatin E (MMAE), to form the antibody-drug conjugate (ADC) Enfortumab vedotin. This ADC is specifically designed for research into locally advanced and metastatic urothelial carcinoma, offering a targeted approach to study the therapeutic efficacy and mechanism of action in these cancer models.